Literature DB >> 12647195

Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.

Johannes G Liese1, Eva Grill, Birgit Fischer, Irmgard Roeckl-Wiedmann, David Carr, Bernd H Belohradsky.   

Abstract

UNLABELLED: Premature infants have an increased risk of developing complicated respiratory syncytial virus (RSV) infections. Epidemiological data on RSV-related hospitalizations are a prerequisite to develop guidelines for the use of preventive measures. The objective of this study was to determine incidence and risk factors of RSV-related rehospitalizations (RSV-RH) of premature infants. We recruited 1,103 infants with a gestational age of less than 35 weeks, primarily admitted to nine neonatologic care units in southern Germany between Nov. 1, 1998 and Oct. 31, 1999. Questionnaires were sent to all parents of infants discharged from neonatal care units to determine the risk of rehospitalization for acute respiratory infections (ARI-RH) and RSV-RH in the 1999-2000 season. The questionnaire response rate was 68.4%. The 717 included infants of the responders had a mean gestational age of 31.6 weeks (Range: 23-35) and a mean birth weight of 1,747 g (range: 430-4,050 g). The risk for an ARI-RH was 10.6% and the risk for RSV-RH 5.2% during the observation period. Premature infants with chronic lung disease (CLD) had a probability of 24.5% for ARI-RH and of 15% for RSV-RH. The following factors were independently associated with an increased risk of RSV-RH: male gender (adjusted Odds-Ratio (OR): 8.7; 95% confidence interval (CI): 2.6-29.1), chronic lung disease (OR: 3.99; 95%CI: 1.4-11.2), discharge between October and December (OR: 2.1; 95%CI: 0.99-4.4), day-care attendance of siblings (OR: 3.9; 95%CI: 1.9-8.3).
CONCLUSIONS: The risk for RSV rehospitalization among premature infants discharged from neonatal care facilities in southern Germany was low. Additional risk factors and high costs of prophylaxis have to be considered when infants are selected for RSV prophylaxis using monoclonal antibodies.

Entities:  

Mesh:

Year:  2003        PMID: 12647195     DOI: 10.1007/s00431-002-1105-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  44 in total

1.  Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

Authors:  G Cilla; A Sarasua; M Montes; N Arostegui; D Vicente; E Pérez-Yarza; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

3.  Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.

Authors:  B Resch; W Gusenleitner; W D Müller; J Haas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

4.  Human rhinoviruses in severe respiratory disease in very low birth weight infants.

Authors:  E Kathryn Miller; Jimena Bugna; Romina Libster; Bryan E Shepherd; Paula M Scalzo; Patricio L Acosta; Diego Hijano; Natalia Reynoso; Juan P Batalle; Silvina Coviello; M Ines Klein; Gabriela Bauer; Alicia Benitez; Steven R Kleeberger; Fernando P Polack
Journal:  Pediatrics       Date:  2011-12-26       Impact factor: 7.124

5.  RSV infection among children born moderately preterm in a community-based cohort.

Authors:  Rolof G P Gijtenbeek; Jorien M Kerstjens; Sijmen A Reijneveld; Eric J Duiverman; Arend F Bos; Elianne J L E Vrijlandt
Journal:  Eur J Pediatr       Date:  2014-09-06       Impact factor: 3.183

6.  At-risk characteristics for hospital admissions and ED visits.

Authors:  Shannon M Hudson; Martina Mueller; William H Hester; Gayenell S Magwood; Susan D Newman; Marilyn A Laken
Journal:  J Spec Pediatr Nurs       Date:  2014-03-03       Impact factor: 1.260

Review 7.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

8.  Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Authors:  Caroline Fenton; Lesley J Scott; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database.

Authors:  Arne Simon; Roland A Ammann; Anja Wilkesmann; Anna M Eis-Hübinger; Oliver Schildgen; Edda Weimann; Hans U Peltner; Peter Seiffert; Angela Süss-Grafeo; Jessie R Groothuis; Johannes Liese; Ralf Pallacks; Andreas Müller
Journal:  Eur J Pediatr       Date:  2007-02-16       Impact factor: 3.183

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.